Shares of argenx SE – (NASDAQ:ARGX) have been given an average rating of “Buy” by the nine analysts that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $142.83.
Several equities analysts recently weighed in on the company. Wedbush raised their price objective on argenx from $93.00 to $114.00 and gave the company an “outperform” rating in a research note on Monday, June 25th. Nomura began coverage on argenx in a report on Friday, June 29th. They set a “buy” rating and a $161.00 target price on the stock. Cowen reiterated a “buy” rating on shares of argenx in a report on Thursday, June 14th. JMP Securities increased their target price on argenx from $93.00 to $130.00 and gave the company a “positive” rating in a report on Monday, June 18th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $154.00 target price on shares of argenx in a report on Monday, September 17th.
NASDAQ ARGX traded down $1.94 during mid-day trading on Monday, hitting $70.76. The stock had a trading volume of 240,900 shares, compared to its average volume of 169,352. argenx has a 52-week low of $22.21 and a 52-week high of $103.00. The company has a market capitalization of $2.44 billion, a P/E ratio of -50.53 and a beta of 2.43.
Large investors have recently made changes to their positions in the business. Atria Investments LLC acquired a new stake in argenx during the 2nd quarter valued at $213,000. Fred Alger Management Inc. grew its holdings in argenx by 50.0% during the 2nd quarter. Fred Alger Management Inc. now owns 3,000 shares of the company’s stock valued at $249,000 after buying an additional 1,000 shares during the last quarter. Aperio Group LLC acquired a new stake in argenx during the 1st quarter valued at $268,000. Dimensional Fund Advisors LP acquired a new stake in argenx during the 1st quarter valued at $498,000. Finally, US Bancorp DE acquired a new stake in argenx during the 1st quarter valued at $598,000. Hedge funds and other institutional investors own 56.14% of the company’s stock.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
See Also: Short Selling Stocks and Day Traders
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.